---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-034907"
form_type: "8-K"
ticker: "TLPH"
cik: "0001427925"
company_name: "TALPHERA, INC."
filed_at: "2024-11-13T23:59:59+00:00"
generated_at: "2026-05-30T00:51:46.843307+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Talphera Q3 net loss widens to $3.4M; NEPHRO CRRT study enrollment underway

## Summary
- Net loss $3.4M ($0.13/share) vs $1.4M ($0.08) in Q3 2023; cash and investments $11.1M.
- Five clinical sites screening for NEPHRO CRRT study; two more expected in Q4; study completion anticipated in 2025.
- Combined R&D and SG&A expenses $3.7M, up from $3.4M, driven by NEPHRO study costs.
- DSUVIA divestment classified as discontinued operations; no related expenses in Q3 2024.

## SEC filing metadata
- accession: 0001437749-24-034907
- form_type: 8-K
- ticker: TLPH
- cik: 0001427925
- company_name: TALPHERA, INC.
- filed_at: 2024-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1427925/000143774924034907/0001437749-24-034907-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1427925/000143774924034907/acrx20241112_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-034907
- JSON: https://secwatch.observer/filing/0001437749-24-034907.json
- Plain text: https://secwatch.observer/filing/0001437749-24-034907.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.